BioLineRx Historical Income Statement
| BLRX Stock | USD 0.75 0.07 8.54% |
Historical analysis of BioLineRx income statement accounts such as Interest Expense of 2.3 M, Selling General Administrative of 17.5 M or Selling And Marketing Expenses of 15.3 M can show how well BioLineRx performed in making a profits. Evaluating BioLineRx income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioLineRx's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BioLineRx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioLineRx is a good buy for the upcoming year.
BioLineRx |
About BioLineRx Income Statement Analysis
BioLineRx Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioLineRx shareholders. The income statement also shows BioLineRx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BioLineRx Income Statement Chart
BioLineRx Income Statement is one of the three primary financial statements used for reporting BioLineRx's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of BioLineRx revenue and expense. BioLineRx Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, BioLineRx's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 17.5 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.1 M in 2024. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioLineRx. It is also known as BioLineRx overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from BioLineRx operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of BioLineRx is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from BioLineRx's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 17.5 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.1 M in 2024.
BioLineRx income statement Correlations
Click cells to compare fundamentals
BioLineRx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioLineRx income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.2M | 589K | 1.3M | 7.0M | 1.4M | 1.1M | |
| Interest Expense | 1.8M | 1.5M | 984K | 2.2M | 2.1M | 2.3M | |
| Selling General Administrative | 3.7M | 3.8M | 4.3M | 5.1M | 16.6M | 17.5M | |
| Selling And Marketing Expenses | 1.4M | 857K | 840K | 6.5M | 14.6M | 15.3M | |
| Gross Profit | (940K) | (934K) | (702K) | (654K) | 174K | 165.3K | |
| Other Operating Expenses | 28.1M | 22.9M | 24.8M | 29.2M | 47.8M | 26.3M | |
| Operating Income | (28.1M) | (22.9M) | (24.8M) | (29.2M) | (43.0M) | (40.8M) | |
| Ebit | (28.1M) | (22.9M) | (24.8M) | (29.2M) | (43.0M) | (40.8M) | |
| Research Development | 23.4M | 18.2M | 19.5M | 17.6M | 11.9M | 17.3M | |
| Ebitda | (26.9M) | (22.3M) | (23.4M) | (22.1M) | (41.6M) | (39.5M) | |
| Cost Of Revenue | 940K | 934K | 702K | 654K | 4.6M | 4.5M | |
| Total Operating Expenses | 28.1M | 22.9M | 24.8M | 29.2M | 43.2M | 25.4M | |
| Income Before Tax | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (57.6M) | |
| Total Other Income Expense Net | 2.7M | (7.1M) | (2.3M) | 4.2M | (17.6M) | (16.7M) | |
| Net Income Applicable To Common Shares | (23.0M) | (25.4M) | (30.0M) | (27.1M) | (24.3M) | (25.6M) | |
| Net Income | (26.8M) | (30.9M) | (28.1M) | (18.9M) | (60.6M) | (57.6M) | |
| Income Tax Expense | 1.4M | 911K | 1.1M | (6.1M) | (5.5M) | (5.2M) | |
| Net Income From Continuing Ops | (25.4M) | (30.0M) | (27.1M) | (25.0M) | (60.6M) | (57.6M) | |
| Interest Income | 777K | 236K | 559K | 694K | 2.0M | 2.1M | |
| Net Interest Income | (1.1M) | (1.3M) | (447K) | (1.1M) | (162K) | (170.1K) | |
| Reconciled Depreciation | 940K | 934K | 703K | 654K | 1.4M | 886.4K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioLineRx offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioLineRx's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biolinerx Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biolinerx Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for BioLineRx Stock analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is BioLineRx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. If investors know BioLineRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioLineRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.76) | Revenue Per Share 0.075 | Return On Assets (0.38) | Return On Equity (1.89) |
The market value of BioLineRx is measured differently than its book value, which is the value of BioLineRx that is recorded on the company's balance sheet. Investors also form their own opinion of BioLineRx's value that differs from its market value or its book value, called intrinsic value, which is BioLineRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioLineRx's market value can be influenced by many factors that don't directly affect BioLineRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.